This result was replicated in a similar but larger investigation ( N = 1,735) comparing all available GLP-1RAs versus non-GLP-1RA antidiabetics, with this antidepressant association possibly correlating with changes in markers of systemic inflammation (that is, high-sensitivity C-reactive protein) 192
Although its license indication is for Type 2 Diabetes, recent clinical trials have been completed, and Semaglutide is pending regulatory approval to treat weight loss and obesity
Common side effects of semaglutide include nausea, vomiting, diarrhea, constipation, headaches, and dizziness
Another approach is to use it less frequently
It starts working as soon as it is injected
targets dullness, spots, and fine lines